期刊
SEMINARS IN ONCOLOGY
卷 42, 期 3, 页码 506-513出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.seminoncol.2015.02.003
关键词
-
类别
资金
- Associazione Italiana per la Ricerca sul Cancro [IG 11746]
- Italian Ministry of Health (MM)
- Astex Pharmaceuticals
Epigenetic alterations play a pivotal role in cancer development and progression. Pharmacologic reversion of such alterations is feasible, and second generation epigenetic drugs are in development and have been demonstrated to possess significant immunomodulatory properties. This knowledge, together with the availability of new and highly effective immunotherapeutic agents including immune checkpoint(s) blocking monoclonal antibodies, allows us to plan for highly innovative proof-of-principle combination studies that will likely open the path to more effective anticancer therapies. (C) 2015 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据